Post hoc subgroup analysis of data from a phase III , randomized , double-blind clinical trial evaluated whether the efficacy of aprepitant triple therapy ( ondansetron and dexamethasone plus aprepitant ) versus control ( ondansetron and dexamethasone ) varies by gender , age , or region in 848 men and women 18 years old with histologically confirmed malignancies and who were nave to moderately or highly emetogenic chemotherapeutic agents .